Aura Biosciences, Inc. Investing Cash Flow
Aura Biosciences, Inc. (AURA) reported Investing Cash Flow of -$171.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$226.03M, a 1231.48% decline year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $54.90M, a 84.14% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $29.82M, a 0.43% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$44.02M, a 545.13% decline year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $35.59M, a 48.28% decline from fiscal 2024.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $68.82M.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$113.96M.
- Aura Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$67.87M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$226.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$171.14M 10-Q · filed 2026-08-11 | -$141.31M derived: sum of 3 quarters · filed 2026-08-11 | -$185.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $54.90M 10-Q · filed 2026-05-11 | $84.72M derived: sum of 2 quarters · filed 2026-05-11 | $40.70M derived: sum of 3 quarters · filed 2026-05-11 | $60.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $29.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$14.20M derived: sum of 2 quarters · filed 2026-03-30 | $5.78M derived: sum of 3 quarters · filed 2026-08-11 | $35.59M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$44.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$24.04M derived: sum of 2 quarters · filed 2026-08-11 | $5.77M 10-Q · filed 2025-11-13 | $35.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $19.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $49.79M 10-Q · filed 2026-08-11 | $79.48M derived: sum of 3 quarters · filed 2026-08-11 | $89.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $29.81M 10-Q · filed 2026-05-11 | $59.51M derived: sum of 2 quarters · filed 2026-05-11 | $69.40M derived: sum of 3 quarters · filed 2026-05-11 | $89.24M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $29.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $39.58M derived: sum of 2 quarters · filed 2026-03-30 | $59.42M derived: sum of 3 quarters · filed 2026-03-30 | $68.82M 10-K · filed 2026-03-30 |
| 2024-09-30 | $9.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $29.73M derived: sum of 2 quarters · filed 2025-11-13 | $39.13M 10-Q · filed 2025-11-13 | -$50.99M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $19.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $29.24M 10-Q · filed 2025-08-13 | -$60.88M derived: sum of 3 quarters · filed 2025-08-13 | -$39.25M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $9.40M 10-Q · filed 2025-05-15 | -$80.72M derived: sum of 2 quarters · filed 2025-05-15 | -$59.09M derived: sum of 3 quarters · filed 2025-05-15 | -$37.69M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$90.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$68.49M derived: sum of 2 quarters · filed 2025-03-24 | -$47.08M derived: sum of 3 quarters · filed 2025-03-24 | -$113.96M 10-K · filed 2025-03-24 |
| 2023-09-30 | $21.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $43.04M derived: sum of 2 quarters · filed 2024-11-12 | -$23.84M 10-Q · filed 2024-11-12 | -$40.72M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $21.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$45.47M 10-Q · filed 2024-08-08 | -$62.35M derived: sum of 3 quarters · filed 2024-08-08 | -$44.40M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$66.88M 10-Q · filed 2024-05-09 | -$83.75M derived: sum of 2 quarters · filed 2024-05-09 | -$65.81M derived: sum of 3 quarters · filed 2024-05-09 | -$109.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.07M derived: sum of 2 quarters · filed 2024-03-27 | -$42.37M derived: sum of 3 quarters · filed 2024-03-27 | -$67.87M 10-K · filed 2024-03-27 |
| 2022-09-30 | $17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$25.50M derived: sum of 2 quarters · filed 2023-11-09 | -$50.99M 10-Q · filed 2023-11-09 | -$51.81M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$43.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$68.94M 10-Q · filed 2023-08-09 | -$69.76M derived: sum of 3 quarters · filed 2023-08-09 | -$70.33M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$25.50M 10-Q · filed 2023-05-11 | -$26.32M derived: sum of 2 quarters · filed 2023-05-11 | -$26.89M derived: sum of 3 quarters · filed 2023-05-11 | -$27.55M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$819.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$1.39M derived: sum of 2 quarters · filed 2023-03-15 | -$2.05M derived: sum of 3 quarters · filed 2023-03-15 | -$2.13M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$573.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.24M derived: sum of 2 quarters · filed 2022-11-10 | -$1.31M 10-Q · filed 2022-11-10 | -$1.44M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$662.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$733.00K 10-Q · filed 2022-08-11 | -$865.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$71.00K 10-Q · filed 2022-05-12 | -$203.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$771.00K 10-K · filed 2022-03-23 | ||
| 2020-09-30 | -$639.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |